7,541.40

-38.67

-0.51%

51,983.98

+213.67

+0.41%

25,164.32

-272.68

-1.07%

2,805.88

-5.97

-0.21%

4.8940

-0.0350

-0.71%

21.15

+1.73

+8.91%

3,956.60

+57.70

+1.48%

76,724.58

-979.50

-1.26%

Crude Oil Dec 26

96.26

-7.86

-7.55%

US Private Equity

10,850.63

-82.20

-0.75%

LIVE It’s John Ternus’ first earnings call as Apple CEO. Listen in here.

NasdaqCM - Delayed Quote USD

Aptevo Therapeutics Inc. (APVO)

1.3500 +0.0100 (+0.75%)

At close: 4:00:00 PM EST

Loading Chart for APVO

Chart Range Bar

Interval:

In partnership with ChartIQ

APVO: Mipletamig Combination Therapy Leads to 21% Stem Cell Transplantation Rate

APVO: Mipletamig Combination Therapy Leads to 21% Stem Cell Transplantation Rate

Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant

Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant

Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting

Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting

Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development

Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development

Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML

Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML

Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML

Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML

APVO: Focusing on Three Key Areas of Development

APVO: Focusing on Three Key Areas of Development

Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results

Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results

Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds

Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds

Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone

Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone

Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors

Mobilize your Website

View Site in Mobile | Classic

Share by: